IL326327A - Treatment of prostate cancer - Google Patents

Treatment of prostate cancer

Info

Publication number
IL326327A
IL326327A IL326327A IL32632726A IL326327A IL 326327 A IL326327 A IL 326327A IL 326327 A IL326327 A IL 326327A IL 32632726 A IL32632726 A IL 32632726A IL 326327 A IL326327 A IL 326327A
Authority
IL
Israel
Prior art keywords
treatment
prostate cancer
prostate
cancer
Prior art date
Application number
IL326327A
Other languages
Hebrew (he)
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of IL326327A publication Critical patent/IL326327A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL326327A 2023-08-04 2024-08-02 Treatment of prostate cancer IL326327A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363517672P 2023-08-04 2023-08-04
US202363603336P 2023-11-28 2023-11-28
US202463617895P 2024-01-05 2024-01-05
US202463670485P 2024-07-12 2024-07-12
PCT/US2024/040691 WO2025034543A1 (en) 2023-08-04 2024-08-02 Treatment of prostate cancer

Publications (1)

Publication Number Publication Date
IL326327A true IL326327A (en) 2026-04-01

Family

ID=94535189

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326327A IL326327A (en) 2023-08-04 2024-08-02 Treatment of prostate cancer

Country Status (5)

Country Link
CN (1) CN121925261A (en)
AU (1) AU2024323161A1 (en)
IL (1) IL326327A (en)
MX (1) MX2026001352A (en)
WO (1) WO2025034543A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3746446T3 (en) * 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2 inhibitors
US12252493B2 (en) * 2019-06-05 2025-03-18 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
EP4630004A1 (en) * 2022-12-05 2025-10-15 Oric Pharmaceuticals, Inc. Treatment of prostate cancer having androgen receptor variants

Also Published As

Publication number Publication date
WO2025034543A1 (en) 2025-02-13
CN121925261A (en) 2026-04-24
MX2026001352A (en) 2026-03-02
AU2024323161A1 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
IL320743A (en) Method of treating prostate cancer
GB202116903D0 (en) Lasofoxifene treatment of aromatase-resistant er+ cancer
IL307381A (en) Diagnostic methods of prostate cancer
GB202107994D0 (en) Treatment of cancer
IL314687A (en) Treatment of cancer
IL326327A (en) Treatment of prostate cancer
IL312155A (en) Method of cancer treatment
IL314798A (en) Methods of treating prostate cancer
CA3300083A1 (en) Treatment of prostate cancer
GB202311976D0 (en) Treatment of cancer
GB202218181D0 (en) Treatment of cancer
GB202201803D0 (en) Treatment of Cancer
IL315569A (en) Methods of treating cancer
GB202018062D0 (en) Treatment of cancer
GB202008037D0 (en) Treatment of cancer
HK40122526A (en) Methods of treating prostate cancer
IL325454A (en) Method of treating prostate cancer
HK40087831A (en) Methods of treating prostate cancer
IL312332A (en) Methods of treating cancer
IL325782A (en) Methods of personalizing cancer treatment
GB202507447D0 (en) Treatment of cancer
GB202505194D0 (en) Treatment of cancer
GB202416582D0 (en) Treatment of cancer
GB202415608D0 (en) Treatment of cancer
GB202406860D0 (en) Treatment of cancer